You are here: Home / Events / Molecular therapies for liver disease in alpha-1 antitrypsin deficiency

Molecular therapies for liver disease in alpha-1 antitrypsin deficiency

September 20-21, 2019

The meeting is focused on therapy of the liver disease in α1-antitrypsin deficiency (AATD) and is addressed to clinicians and basic science researchers. The conference will provide a comprehensive overview and detailed lectures on cutting-edge translational and clinical research and will foster the exchange of ideas among AATD investigators. The sessions will be covered with lectures of distinguished experts as well as short oral and poster presentations of the most recent results of the attending researchers.
The meeting will take place in Pozzuoli (Italy), in the Naples metropolitan area, at the Telethon Institute of Genetics and Medicine (TIGEM). TIGEM is part of Telethon Foundation, a leading Italian charity organization investing in the research of rare genetic diseases.

Organizers:
Nicola Brunetti-Pierri
Telethon Institute of Genetics and Medicine, IT

Pasquale Piccolo
Telethon Institute of Genetics and Medicine, IT

Pavel Strnad
RWTH Aachen, DE

Speakers:
Nedim Hadzic
King's College London, UK

Ron Kopito
Stanford University, US

David Lomas
University College London, UK

Christian Mueller
University of Massachusetts, US

Jeffrey Teckman
Saint Louis University, US

Application period
May 1 – July 15, 2019

Abstract submission period
April 1 – June 30, 2019

Participation fees:
Academics/Principal Investigators: 100€
Student/Post-docs: 50€

Contact

Provisional program:
September 20th, 2019
Session 1: Clinical spectrum of liver disease in AATD
Session 2: Therapeutic approaches to liver disease in AATD

September 21st, 2019
Session 3: New therapeutic targets: recent advances from basic science
Session 4: New tools for therapy discovery and development

Download the poster